Proxy Votes Now

Home › Funds › ProShares › Pharmaceuticals Ultrasector Profund

Pharmaceuticals Ultrasector Profund (PHPIX) proxy voting record 2025-2026

Fund family: ProShares · Filed by ProFunds (CIK 1039803) · SEC series S000003093

Share classes and tickers: PHPIX (C000008401), PHPSX (C000008402)

“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 425 with, 12 against, 0 abstentions (not counted as with management). Shareholder proposals: 2 FOR, 7 AGAINST, 0 abstained, by the filing’s own vote-source field.

Compared with ProShares as a whole

The same two figures as ProShares’s manager page (303,945 ballot items across 135 funds and accounts), counted the same way for this fund.

2025-2026This fundItemsProSharesItems
Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters)86.4%41391.4%279,029
Backed environmental and social shareholder proposals at US companiesn/a410.6%4,043

Where this fund voted differently from most ProShares funds

Each ballot item this fund voted is set against the votes of the other ProShares funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.

Voted the same way as most ProShares funds on all 405 items where a comparison was possible.

Votes against management by sector

The same votes as “with management” above, by the sector of the company voted on. 97.0% of this fund’s 437 such votes could be given a sector; the other 13 (3.0%) are at companies without one and are not in the table.

SectorVotesAgainst managementShare
Health Care413122.9%
Industrials1100.0%

What it voted on

Ballot items by the category the filing put first; “against management” as above.
Proposal typeItemsAgainst management
Director Elections2803
Say-on-Pay560
Audit-related520
Compensation210
Corporate Governance145
Capital Structure120
Shareholder Rights and Defenses30
Environment or Climate22
Extraordinary Transactions20
Other Social Issues22

Its largest holdings’ meetings

Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.

CompanyMeetingEst. positionItemsAgainst mgmt
Xeris Biopharma Holdings, Inc.June 4, 2026$122,52840
Viatris Inc.December 5, 2025$110,129150
Organon & Co.June 9, 2026$96,494130
Viatris Inc.May 15, 2026$94,222150
Amneal Pharmaceuticals, Inc.May 6, 2026$91,629120
Corcept Therapeutics IncorporatedMay 21, 2026$91,094110
Amylyx Pharmaceuticals, Inc.June 4, 2026$82,67740
Eli Lilly and CompanyMay 4, 2026$80,279102

Notable votes against management

MeetingCompanyProposalFundMgmt
May 4, 2026Eli Lilly and CompanyShareholder proposal to adopt a policy and amend the bylaws to require an independent board chair. Shareholder proposalForAgainst
May 4, 2026Eli Lilly and CompanyShareholder proposal to prepare an annual lobbying report. Shareholder proposalAgainstFor
April 23, 2026Johnson & JohnsonIndependent Board Chair Shareholder proposalAgainstFor
June 9, 2026Pacira Biosciences, Inc.Election of three Class III directors to our board of directors to serve until the 2029 annual meeting of stockholders and until their successors are duly elected and qualified: Company Nominees: DOMA Nominees Opposed by the Company: Oliver Benton Curtis III Shareholder proposalWithholdFor
June 9, 2026Pacira Biosciences, Inc.Election of three Class III directors to our board of directors to serve until the 2029 annual meeting of stockholders and until their successors are duly elected and qualified: Company Nominees: DOMA Nominees Opposed by the Company: Eric de Armas Shareholder proposalWithholdFor
May 5, 2026Bristol-Myers Squibb CompanyShareholder Proposal on the Adoption of a Board Policy that the Chairperson of the Board be an Independent Director Shareholder proposalAgainstFor
April 23, 2026Pfizer Inc.Adopt an Independent Chair Policy Shareholder proposalAgainstFor
May 26, 2026Merck & Co., Inc.Shareholder proposal regarding a report on DEI risks in federal contracting. Shareholder proposalAgainstFor
May 26, 2026Merck & Co., Inc.Shareholder proposal regarding a report on healthcare coverage gaps. Shareholder proposalAgainstFor
May 20, 2026Zoetis Inc.Shareholder proposal to permit shareholder action by written consent. Shareholder proposalForAgainst

Contested meetings

Meetings with a proxy contest or competing nominees (1 in 2025-2026), and how the fund voted the items on its ballot.

Funds that vote the same way

These funds reported the same votes as Pharmaceuticals Ultrasector Profund in the latest season (or all but a few items), so they share this page:

Search this fund’s votes by company

444 ballot items at 53 meetings in 2025-2026. Download all votes (CSV)

Recent notable votes

Recent votes against management’s recommendation at large companies.

About this fund’s record

In the 2025-2026 proxy season, Pharmaceuticals Ultrasector Profund (PHPIX) voted at 53 shareholder meetings of 50 companies, on 444 ballot items in all. Where management made a recommendation, the fund followed it on 97.3% of the items and voted against it 12 times. Its most frequent area of disagreement was corporate governance (5 of its votes against management). It voted on 12 shareholder proposals. It voted FOR the board's own proposals less often than ProShares's funds as a whole (86.4% against 91.4%). It voted the same way as most ProShares funds on every item where a comparison was possible. 1 of its meetings was contested.

About this page

Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of ProShares’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.